[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004076453A1 - Novel diazabicyclic aryl derivatives - Google Patents

Novel diazabicyclic aryl derivatives Download PDF

Info

Publication number
WO2004076453A1
WO2004076453A1 PCT/EP2004/050079 EP2004050079W WO2004076453A1 WO 2004076453 A1 WO2004076453 A1 WO 2004076453A1 EP 2004050079 W EP2004050079 W EP 2004050079W WO 2004076453 A1 WO2004076453 A1 WO 2004076453A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
diaza
furan
bicyclo
Prior art date
Application number
PCT/EP2004/050079
Other languages
French (fr)
Inventor
Dan Peters
Gunnar M. Olsen
Elsebet Østergaard NIELSEN
Tino Dyhring Jørgensen
Philip K. Ahring
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ540998A priority Critical patent/NZ540998A/en
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to EP04707948A priority patent/EP1599476B1/en
Priority to AU2004215658A priority patent/AU2004215658B2/en
Priority to JP2006502001A priority patent/JP2006519208A/en
Priority to US10/547,157 priority patent/US7678788B2/en
Priority to MXPA05006861A priority patent/MXPA05006861A/en
Priority to DE602004023586T priority patent/DE602004023586D1/en
Priority to AT04707948T priority patent/ATE445618T1/en
Priority to CA002518675A priority patent/CA2518675A1/en
Priority to BR0407216-2A priority patent/BRPI0407216A/en
Publication of WO2004076453A1 publication Critical patent/WO2004076453A1/en
Priority to HK06104352A priority patent/HK1084110A1/en
Priority to US12/694,952 priority patent/US20100130483A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
  • CNS central nervous system
  • PNS peripheral nervous system
  • acetylcholine exert its biological effect via two types of cholinergic receptors, the muscari ⁇ ic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).
  • mAChR muscari ⁇ ic Acetyl Choline Receptors
  • nAChR nicotinic Acetyl Choline Receptors
  • muscarinic acetylcholine receptors dominate quantitatively over nicotinic acetylcholine receptors in the brain area important to memory and cognition, and much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscari ⁇ ic acetylcholine receptor modulators.
  • WO 00/58311 discloses 1 ,4-diazabicyclo[3.2.2]nonane-4-carboxylates and carboxamide derivatives useful as inhibitors of the nicotinic al receptor subtype. Other 1 ,4-diazabicyclo[3.2.2]nonane-4-methanone derivatives are not disclosed.
  • the present invention is devoted to the provision novel modulators of the nicotinic receptors, which modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine 7 receptor subtype.
  • the compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging), and they may be used in labelled or u ⁇ labelled form.
  • the invention provides diazabicyclic aryl derivatives of
  • n 1 , 2 or 3;
  • X and Y independently of one another, represents CR 2 , CR 3 and/or N, wherein R 2 and R 3 , independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, aryl-alkyl, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, aryl-alkyl, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
  • R 1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S0 2 NH- or (R'S0 2 ) 2 N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkenyl, phenyl or benzyl; or a group of formula aryl-alkyl-, aryl- Z-(alkyl) m -, aryl-C ⁇ C-, heteroary
  • R 1 and R 2 , or R 1 and R 3 together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
  • compositions comprising a therapeutical ly effective amount of the diazabicyclic aryl derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
  • the invention relates to the use of the diazabicyclic aryl derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of pharmaceutical compositions/medicaments for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors.
  • the invention provides a method for treatment, prevention or alleviation of diseases, disorders or conditions of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors, and which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the diazabicyclic aryl derivative of the invention.
  • the invention provides a diazabicyclic aryl derivative of Formula I
  • n 1 , 2 or 3;
  • X and Y independently of one another, represents CR 2 , CR 3 and/or N, wherein R 2 and R 3 , independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, aryl-alkyl, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, aryl-alkyl, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
  • R 1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S0 2 NH- or (R'S0 2 ) 2 N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkenyl, phenyl or benzyl; or a group of formula aryl-alkyl-, aryl- Z-(alkyl) m -, aryl-C ⁇ C-, heteroary
  • R 1 and R 2 , or R and R 3 together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
  • the invention provides a diazabicyclic aryl derivative of Formula I, wherein
  • X represents CR 3 or N, wherein R 3 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halogen, CF 3 , OCF 3 , CN, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy;
  • R 1 and R 2 independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halogen, CF 3 , OCF 3 , CN, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy; or
  • R 1 and R 2 together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring.
  • the invention provides a diazabicyclic aryl derivative of Formula I, wherein
  • X and Y independently of one another, represents CR 2 or N, wherein R 2 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro, and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
  • R 1 represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro, and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; or
  • R 1 and R 2 together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionalle be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
  • aryl is selected from the group consisting of phenyl, indenyl and naphthyl; and heteroaryl represents an aromatic 5- and 6-membered monocyclic heterocyclic group selected from the group consisting of furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; pyrralyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2-, 4- or 5-yl; imidazolyl, in particular imidazol-2- or 4-yl; pyrazolyl, in particular pyrazol-1-, 3- or 4-yl; isoxazolyl, in particular isoxazol-3-, 4- or 5-yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl, thiadiazolyl, in particular 1 ,3,4- thiadiazol-2-yl, pyridyl, in particular
  • aryl represents phenyl; aryl-alkyl represents benzyl; and heteroaryl represents furanyl, in particular furan-2- or 3-yl; imidazolyl, in particular imidazol-2- or 4-yl; isoxazolyl, in particular isoxazol-3-, 4- or 5- yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl, thiadiazolyl, in particular 1 ,3,4- thiadiazol-2-yl, pyridyl, in particular pyrid-2-, 3- or 4-yl; or indolyl, in particular indol-2-, 3-, 5- or 6-yl.
  • the invention provides a diazabicyclic aryl derivative of Formula I, la, lb, II or 111, wherein n is 1 , 2 or 3.
  • the diazabicyclic aryl of the invention is a diazabicyclic aryl derivative of Formula I, la, lb, II or 111, wherein n is 2.
  • the invention provides a diazabicyclic aryl derivative of Formula I, wherein at least one of X and Y represents N; and the other of X and Y represent CR 2 ; and n, R 1 and R 2 are as defined above.
  • the invention provides a diazabicyclic aryl derivative of Formula la or lb,
  • n and R1 are as defined above.
  • the invention provides a diazabicyclic aryl derivative of Formula lc or Id,
  • R1 is as defined above.
  • the invention provides a diazabicyclic aryl derivative of Formula I, wherein one or two of R 2 and R 3 , independently of one another, represent hydrogen and/or halo; and R 1 and the remainder of R 2 and R 3 , independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, halo, CF 3 , OCF 3 , CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4-methyl- phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl- phenyl, 2-halo-5-trifluoromethyl-phenyl, 2-ami ⁇ o-phenyl, 2-amino-4-methyl-phenyl, 3- amino-phenyl, 4-amino-phenyl, 2-ami ⁇ o-4-methyl-phenyl, 4-halo-phenyl,
  • the invention provides a diazabicyclic aryl derivative of Formula I, wherein one of R 1 and R 2 represents phenyl or naphthyl; and the other of R 1 and R 2 represents hydrogen.
  • the invention provides a diazabicyclic aryl derivative of Formula I, wherein both of X and Y represent CR 2 , CR 3 or N, wherein R 2 and R 3 , independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; or X represents N or CR 2 , wherein R 2 represents hydrogen, alkyl
  • the invention provides a diazabicyclic aryl derivative of Formula II,
  • R 1 and R 2 independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, phenyl, phenyloxy, heteroaryl and/or heteroaryloxy, which phenyl, phenyloxy, heteroaryl and heteroaryloxy may optionally be substituted one or two times with alkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, a group of the formula R'CONH-, R'S0 2 NH- and/or (R'S0 2 ) 2 N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alke ⁇ yl, phenyl or benzyl; wherein R' represents hydrogen or alkyl
  • R 1 and R 2 together with the carbon atoms to which they are bound, form a benzo-fused aromatic benzene ring, which benzene ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
  • diazabicyclic aryl derivative of the invention is a diazabicyclic aryl derivative of Formula II, wherein
  • R 1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halo, CF 3 , OCF 3 , CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4-methyl-phenyl, 3-nitro-phenyl, 4- ⁇ itro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phe ⁇ yl, 2-haIo-5- trifluoromethyl-phenyl, 2-ami ⁇ o-phenyl, 2-amino-4-methyl-phenyl, 3-amino-phenyl, 4- amino-phenyl, 2-amino-4-methyl-phenyl, 4-halo-phe ⁇ yl, 4-formylami ⁇ o-phe ⁇ yl, 2- acetylamino-phenyl, 3-acetylamino-phenyl, 4-acetylamino-phenyl, N-3-phenyl- acetamide, N
  • R 2 represents hydrogen or halo
  • R 4 represents hydrogen, alkyl or halo.
  • the invention provides a diazabicyclic aryl derivative of Formula 111,
  • X represents CR 4 or N, wherein R 4 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy;
  • R 5 and R 6 independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, ' cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy.
  • the diazabicyclic aryl derivative of the invention is a diazabicyclic aryl derivative of Formula III, wherein R 4 rep resents hydrogen or alkyl; R 5 represents hydrogen, alkyl or alkoxy; and R 6 represents hydrogen, alkyl or alkoxy.
  • the invention provides a diazabicyclic aryl derivative of Formula I, la, lb or II, wherein
  • R 1 represents a group of formula -(alkyl) m -Z-aryl, -(alkyl) m -Z-heteroaryl or -C ⁇ C-aryl, wherein m is 0 or 1; and Z represents O or S; and wherein the aryl and heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S0 2 NH- or (R'S0 2 ) 2 N-, wherein R' represents hydrogen or alkyl.
  • the invention provides a diazabicyclic aryl derivative of Formula I or II, wherein R 1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halo, CF 3 , OCF 3 , CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4- methyl-phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 3-trifluoromethyl-phenyl, 4- trifluoromethyl-phenyl, 2-halo-5-trifluoromethyl-phenyl, 2-amino- ⁇ henyl, 2-amino-4- methyl-phenyl, 3-amino-phenyl, 4-ami ⁇ o-phenyl, 2-amino-4-methyl-phenyl, 4-halo- phenyl, 4-formylamino-phenyl, 2-acetylamino-phenyl, 3-acetylamino-phenyl, 4- ace
  • R 2 represents hydrogen, alkyl or halo
  • R 3 represents hydrogen, alkyl or halo.
  • an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain.
  • the hydrocarbon chain preferably contain of from one to eighteen carbon atoms (Ci.is-alkyl), more preferred of from one to six carbon atoms (C ⁇ _ 6 -alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl.
  • alkyl represents a C h alky! group, including butyl, isobutyl, secondary butyl, and tertiary butyl.
  • alkyl represents a C ⁇ _ 3 -alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
  • a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C ⁇ -cycloalkyl), including cyclopropyl, cyclobutyl, cyclope ⁇ tyl, cyclohexyl and cycloheptyl.
  • a cycloalkyl-alkyl group designates a cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl group as also defined above.
  • Examples of preferred cycloalkyl-alkyl groups of the invention include cyclopropylmethyl and cyclopropylethyl.
  • alkoxy group designates an "alkyl-O-" group, wherein alkyl is as defined above.
  • alkyl is as defined above.
  • preferred alkoxy groups of the invention include methoxy and ethoxy.
  • a cycloalkoxy group designates a "cycloalkyl-O-" group, wherein cycloalkyl is as defined above.
  • a cyano-alkyl group designates an alkyl group substituted with CN, wherein alkyl is as defined above.
  • halo represents fluoro, chloro, bromo or iodo
  • haloalkyl group designates an alkyl group as defined herein, which alkyl group is substituted one or more times with halo.
  • a trihalomethyl group represents e.g. a trifluoromethyl group, a trichloromethyl group, and similar trihalo- substituted methyl groups.
  • Preferred haloalkyl groups of the invention include trihalogenmethyl, preferably CF 3 .
  • a haloalkoxy group designates an alkoxy group as defined herein, which alkoxy group is substituted one or more times with halo.
  • Preferred haloalkoxy groups of the invention include trihalogenmethoxy, preferably CF 3 0-.
  • an aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group.
  • preferred aryl groups of the invention include phenyl, indenyl, naphthyl, azulenyl, fluorenyl, and anthracenyl.
  • the most preferred aryl group of the invention is phenyl.
  • an aryloxy group designates an "aryl -0-" group, wherein aryl is as defined above.
  • the most preferred aryloxy group of the invention is phenoxy.
  • heteroaryl group designates an aromatic mono- or polycyclic heterocyclic group, which holds one or more heteroatoms in its ring structure.
  • Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).
  • Preferred 5-6 membered heteroaryl groups of the invention include furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; selenophenyl, in particular selenophen-2- or 3-yl; pyrrolyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2, 4- or 5-yl; thiazolyl, in particular thiazol-2, 4- or 5-yl; imidazolyl, in particular imidazol-2- or 4-yl; pyrazolyl, in particular pyrazol-3- or 4-yl; isoxazolyl, in particular isoxazol-3, 4- or 5-yl; isothiazolyl, in particular isothiazol-3-, 4- or 5-yl; oxadiazolyl, in particular 1 ,2,3- oxadiazol-4- or 5-yl, or 1 ,3,4-ox
  • More preferred 5 membered heteroaryl groups of the invention include furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; pyrrolyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2, 4- or 5-yl; thiazolyl, in particular thiazol-2, 4- or 5-yl; isoxazolyl, in particular isoxazol-3, 4- or 5- yl; isothiazolyl, in particular isothiazol-3-, 4- or 5-yl; and thiadiazolyl, in particular 1 ,2,3-thiadiazol-4- or 5-yl, or 1,3,4-thiadiazol-2-yl.
  • Most preferred 5 membered heteroaryl groups of the invention include furanyl, in particular furan-2- or 3-yl; and thienyl, in particular thien-2- or 3-yl. More preferred 6 membered heteroaryl groups of the invention include pyridyl, in particular pyrid-2-, 3- or 4-yl; and pyrazinyl, in particular pyrazin-2- or 3-yl.
  • an aromatic bicyclic heterocyclic group designates a bicyclic heterocyclic group, which holds one or more heteroatoms in its ring structure.
  • the term "bicyclic heterocyclic group” includes benzo-fused five- and six-membered heterocyclic rings containing one or more heteroatoms. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).
  • Preferred bicyclic heteroaryl groups of the invention include indolizi ⁇ yl, in particular indoIizin-2-, 5- or 6-yl; indolyl, in particular indol-2-, 5- or 6-yl; isoindolyl, in particular isoindol-2-, 5- or 6-yl; benzo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; be ⁇ zo[b]thienyl, in particular benzothien-2-, 5- or 6-yl; benzoimidazolyl, in particular benzoimidazol-2-, 5- or 6-yl; benzothiazolyl, in particular benzothiazol-5- or 6-yl; purinyl, in particular purin-2- or 8-yl; quinolinyl, in particular quinolin-2-, 3-, 6- or 7-yl; isoquinolinyl, in particular isoquinolin-3-, 6- or 7-yl; cinnolinyl
  • More preferred bicyclic heteroaryl groups of the invention include indolyl, in particular indol-2-, 5- or 6-yl; benzo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; benzo[b]thienyl, in particular benzothien-2-, 5- or 6-yl; benzoimidazolyl, in particular benzoimidazol-2-, 5- or 6-yl; and quinoxalinyl, in particular quinoxalin-2- or 6-yl.
  • bicyclic heteroaryl groups of the invention include indolyl, in particular indol-2-, 5- or 6-yl; be ⁇ zo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; benzo[b]thienyl, in particular benzothien-2-, 5- or 6-yl.
  • heteroaryloxy group designates a "heteroaryl-0-" group, wherein heteroaryl is as defined above.
  • the diazabicyclic aryl derivative of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fuma
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
  • Metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.
  • Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysine, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts (aza-onium salts).
  • Preferred aza-onium salts include the alkyl-onium salts, in particular the methyl- and the ethyl-onium salts; the cycloalkyl-onium salts, in particular the cyclopropyl-onium salts; and the cycloalkylalkyl-o ⁇ ium salts, in particular the cyclopropyl-methyl-onium salts.
  • Particularly preferred onium salts of the invention include those created at the N' position according to the following Formula I'
  • the chemical compounds of the present invention may exist in (+) and (-) forms as well as in racemic forms.
  • the racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
  • Racemic forms can be resolved into the optical antipodes by known methods and techniques.
  • One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base.
  • Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix.
  • Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulpho ⁇ ate) salts for example.
  • the chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
  • an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid
  • Optical active compounds can also be prepared from optical active starting materials.
  • the diazabicyclic aryl derivative of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • the present invention is devoted to the provision novel ligands and modulators of the nicotinic receptors, which ligands and modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine receptor (nAChR).
  • Preferred compounds of the invention show a pronounced nicotinic acetylcholine al receptor subtype selectivity.
  • the compounds of the present invention may in particular be agonists, partial agonists, antagonists and/or allosteric modulators of the nicotinic acetylcholine receptor.
  • the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
  • CNS central nervous system
  • PNS peripheral nervous system
  • the compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimagi ⁇ g), and they may be used in labelled or u ⁇ labelled form.
  • the compounds of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system.
  • diseases or disorders includes anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder (ADHD), Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, psychosis, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post- traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome,
  • the compounds of the invention may be useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
  • the compounds of the invention may be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
  • the compounds of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.
  • the compounds of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
  • inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
  • the compounds of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.
  • the pain may in particular be neuropathic pain, chronic headache, central pain, pain related to diabetic neuropathy, to post therapeutic neuralgia, or to peripheral nerve injury.
  • the compounds of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances.
  • addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
  • addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.
  • Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.
  • treatment covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a voluntary diminished intake of the addictive substance.
  • the compounds of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various tissues.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the diazabicyclic aryl derivative of the invention.
  • a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the diazabicyclic aryl derivative of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients, know and used in the art.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • the pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy.
  • Preferred routes of administration include oral administration, in particular in tablet, in capsule, in drage, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection.
  • the pharmaceutical composition of the invention can be manufactured by the skilled person by use of standard methods and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
  • the diazabicyclic aryl derivative of the invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
  • a therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity e.g. ED 50 and LD 50
  • ED 50 and LD 50 may be determined by standard pharmacological procedures in cell cultures or experimental animals.
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD ⁇ o EDso.
  • Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the diazabicyclic aryl derivatives of the present invention are valuable nicotinic receptor modulators, and therefore useful for the treatment of a range of ailments involving cholinergic dysfunction as well as a range of disorders responsive to the action of nAChR modulators.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a diazabicyclic aryl derivative of the invention.
  • treatment covers treatment, prevention, prophylaxis or alleviation
  • the term “disease” covers illnesses, diseases, disorders and conditions related to the disease in question.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o.
  • the upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.
  • 1,4-Diazabicyclo[3.2.2]nonan-3-one (5.12 g; 36 mmol) was dissolved in tetrahydrofuran (50 ml), litium aluminium hydride 2.28 g (60 mmol) was added to the solution and the reaction mixture was refluxed for 36 hours. After cooling the reaction mixture to room temperature, water (2.3 ml) was added dropwise and the mixture was filtered. The solvent was removed from the filtrate by rotavapor at reduced pressure. The formed substance was distilled with Kugelrohr (0.5 mBar, 70°C). Yield of the title compound 3.11 g (68%).
  • the mixture was extracted with diethylether (3 x 100 ml).
  • the combined ether phase was extracted with aqueous sodium hydroxide (3 x 100 ml; 2M).
  • the aqueous phase was cooled on ice and acidified with aqueous hydrochloric acid (100 ml; 10M).
  • the mixture was extracted with ether (3 x 100 ml).
  • the combined ether phase was evaporated. Yield 36 g (54%). Mp. 118.5°C.
  • the title compound was prepared according to Method A, from 5-bromo-2- furoyl chloride (Method B) using no diisopropylethylamine.
  • Aqueous sodium hydroxide (10 ml; 1M) was added.
  • the mixture was extracted with dichloromethane (3 x 10 ml).
  • Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound.
  • the corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Mp. 192.7- 196.4°C.
  • the title compound was prepared according to Method A, from 5-nitro-2- furoyl chloride (Method B), using no diisopropylethylamine. Mp. 242.6-251.0°C.
  • the title compound was prepared according to Method A from 5-oxazoloyl chloride (Method B), using no diisopropylethylamine. Mp. >160°C (decomp.).
  • the title compound was prepared according to Method A from 5-methyI- 1 ,3,4-oxadiazol-2-carbonyl-chloride chloride, using no diisopropylethylamine. Mp. 280-290°C.
  • the mixture was extracted with diethyiether (3 x 100 ml).
  • the combined ether phase was extracted with aqueous sodium hydroxide (3 x 100 ml; 2M).
  • the aqueous phase was cooled on ice and acidified with aqueous hydrochloric acid (100 ml; 10M).
  • the mixture was extracted with ether (3 x 100 ml).
  • the combined ether phase was evaporated. Yield 36 g (54%). Mp. 118.5°C.
  • the title compound was prepared by stirring a mixture of 5-(4-nitrophenyl)- 2-furoic acid (1.0 g; 4.3 mmol) and thionyl chloride (10 ml) at reflux for 2 hours. The mixture was evaporated and co-evaporated with anhydrous toluene. The acid chloride was used without further purification.
  • Acetic acid anhydride (133 mg; 1.3 mmol) solved in dichloromethane (2 ml) was added dropwise to a mixture of (1 ,4-diaza-bicyclo[3.2.2]non-4-yl)-5-(4- aminophenyl)-furan-2-yl-methanone and dichloromethane (10 ml) at room temperature. The mixture was allowed to stir for 4 hours. Aqueous sodium hydroxide (20 ml; 1M) was added followed by extraction with dichloromethane (3 x 20 ml). The crude mixture was purified by silica gel chromatography, using a mixture of dichloromethane : methanol (4:1) and 2% methanol as eluent. The product was isolated as the free base. Mp. 113°C (decomp.).
  • the title compound was prepared according to Method D from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(2-aminophenyl)-furan-2-yl-methanone.
  • the corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Mp. 178.9-185.0°C.
  • the title compound was prepared according to Method D from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(3-aminophenyl)-furan-2-yl-methanone.
  • the corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1 ) saturated with fumaric acid. Mp. 216°C.
  • ⁇ -Bungarotoxine is a peptide isolated from the venom of the Elapidae snake Bungarus muiticinctus. It has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist.
  • 3 H- ⁇ -Bungarotoxine labels nicotinic acetylcholine receptors formed by the subunit isoform found in brain and the oi l isoform in the neuromuscular junction.
  • Preparations are performed at 0 ⁇ 4°C.
  • Cerebral cortices from male Wistar rats (150-250 g) are homogenised for 10 seconds in 15 ml of 20 mM Hepes buffer containing 118 mM NaCI, 4.8 mM KCI, 1.2 mM MgS0 4 and 2.5 mM CaCI 2 (pH 7.5) using an Ultra-Turrax homogeniser.
  • the tissue suspension is subjected to centrifugation at 27,000 x g for 10 minutes.
  • the supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 minutes in 20 ml of fresh buffer, and the final pellet is then re-suspended in fresh buffer containing 0.01% BSA (35 ml per g of original tissue) and used for binding assays.
  • the test value is given as an IC50 (the concentration of the test substance which inhibits the specific binding of 3 H- ⁇ -bungarotoxin by 50%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)

Abstract

This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

Description

NOVEL DIAZABICYCLIC A YL DERIVATIVES
TECHNICAL FIELD
This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
BACKGROUND ART
The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors, the muscariπic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).
As it is well established that muscarinic acetylcholine receptors dominate quantitatively over nicotinic acetylcholine receptors in the brain area important to memory and cognition, and much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscariπic acetylcholine receptor modulators.
Recently, however, an interest in the development of nAChR modulators has emerged. Several diseases are associated with degeneration of the cholinergic system i.e. senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to the organic brain damage disease related directly to alcoholism.
WO 00/58311 discloses 1 ,4-diazabicyclo[3.2.2]nonane-4-carboxylates and carboxamide derivatives useful as inhibitors of the nicotinic al receptor subtype. Other 1 ,4-diazabicyclo[3.2.2]nonane-4-methanone derivatives are not disclosed.
SUMMARY OF THE INVENTION
The present invention is devoted to the provision novel modulators of the nicotinic receptors, which modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine 7 receptor subtype.
The compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimaging), and they may be used in labelled or uπlabelled form. In its first aspect the invention provides diazabicyclic aryl derivatives of
Formula I
Figure imgf000004_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein n is 1 , 2 or 3; and
X and Y, independently of one another, represents CR2, CR3 and/or N, wherein R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, aryl-alkyl, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, aryl-alkyl, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkenyl, phenyl or benzyl; or a group of formula aryl-alkyl-, aryl- Z-(alkyl)m-, aryl-C≡C-, heteroaryl-Z-(alkyl)m- or heteroaryl-C≡C-, wherein m is 0 or 1; and Z represents 0 or S; and wherein the aryl and heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl; or
R1 and R2, or R1 and R3, together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
In a second aspect the invention provides pharmaceutical compositions comprising a therapeutical ly effective amount of the diazabicyclic aryl derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
Viewed from another aspect the invention relates to the use of the diazabicyclic aryl derivative of the invention, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of pharmaceutical compositions/medicaments for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors.
In yet another aspect the invention provides a method for treatment, prevention or alleviation of diseases, disorders or conditions of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors, and which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the diazabicyclic aryl derivative of the invention.
Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.
DETAILED DISCLOSURE OF THE INVENTION
Diazabicyclic Aryl Derivatives
In a first aspect the invention provides a diazabicyclic aryl derivative of Formula I
Figure imgf000005_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein n is 1 , 2 or 3; and
X and Y, independently of one another, represents CR2, CR3 and/or N, wherein R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, aryl-alkyl, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, aryl-alkyl, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkenyl, phenyl or benzyl; or a group of formula aryl-alkyl-, aryl- Z-(alkyl)m-, aryl-C≡C-, heteroaryl-Z-(alkyl)m- or heteroaryl-C≡C-, wherein m is 0 or 1 ; and Z represents O or S; and wherein the aryl and heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl; or
R1 and R2, or R and R3, together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
In a preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, wherein
X represents CR3 or N, wherein R3 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halogen, CF3, OCF3, CN, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy;
R1 and R2, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halogen, CF3, OCF3, CN, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy; or
R1 and R2, together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring.
In another preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, wherein
X and Y, independently of one another, represents CR2 or N, wherein R2 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro, and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
R1 represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro, and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; or
R1 and R2, together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionalle be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
In a more preferred embodiment aryl is selected from the group consisting of phenyl, indenyl and naphthyl; and heteroaryl represents an aromatic 5- and 6-membered monocyclic heterocyclic group selected from the group consisting of furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; pyrralyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2-, 4- or 5-yl; imidazolyl, in particular imidazol-2- or 4-yl; pyrazolyl, in particular pyrazol-1-, 3- or 4-yl; isoxazolyl, in particular isoxazol-3-, 4- or 5-yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl, thiadiazolyl, in particular 1 ,3,4- thiadiazol-2-yl, pyridyl, in particular pyrid-2-, 3- or 4-yl; pyridazinyl, in particular pyridazin-3- or 4-yl; pyrimidinyl, in particular pyrimidin-2-, 4- or 5-yl; and pyrazinyl, in particular pyrazin-2- or 3-yl; or an aromatic bicyclic heterocyclic group the group consisting of indolyl, in particular indol-2-, 3-, 5- or 6-yl, benzo[b]furanyl, in particular benzofuran-2-, 5- or 6-yl; benzo[b]thieπyl, in particular benzothien-2-, 5- or 6-yl; benzoimidazolyl, in particular benzoimidazol-2-, 5- or 6-yl; quinolinyl, in particular quinolin-2-, 3-, 6- or 7-yl; isoquinolinyl, in particular isoquinolin-3-, 6- or 7-yl; and cinnolinyl, in particular cinnolin-6- or 7-yl.
In a even more preferred embodiment aryl represents phenyl; aryl-alkyl represents benzyl; and heteroaryl represents furanyl, in particular furan-2- or 3-yl; imidazolyl, in particular imidazol-2- or 4-yl; isoxazolyl, in particular isoxazol-3-, 4- or 5- yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl, thiadiazolyl, in particular 1 ,3,4- thiadiazol-2-yl, pyridyl, in particular pyrid-2-, 3- or 4-yl; or indolyl, in particular indol-2-, 3-, 5- or 6-yl.
In a third preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, la, lb, II or 111, wherein n is 1 , 2 or 3. In a more preferred embodiment the diazabicyclic aryl of the invention is a diazabicyclic aryl derivative of Formula I, la, lb, II or 111, wherein n is 2.
In a fourth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, wherein at least one of X and Y represents N; and the other of X and Y represent CR2; and n, R1 and R2 are as defined above. In a fifth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula la or lb,
Figure imgf000008_0001
wherein, n and R1 are as defined above.
In a sixth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula lc or Id,
Figure imgf000008_0002
wherein, R1 is as defined above.
In a most preferred embodiment the diazabicyclic aryl derivative of the invention is
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-oxazolyl-5-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-(5-phenyl-oxazol-5-yl)-methanone; or
(1,4-Diaza-bicyclo[3.2.2]non-4-yI)-5-phenyl-1 ,3,4-oxadiazol-2-yl- methanone; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
In a seventh preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, wherein one or two of R2 and R3, independently of one another, represent hydrogen and/or halo; and R1 and the remainder of R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, halo, CF3, OCF3, CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4-methyl- phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl- phenyl, 2-halo-5-trifluoromethyl-phenyl, 2-amiπo-phenyl, 2-amino-4-methyl-phenyl, 3- amino-phenyl, 4-amino-phenyl, 2-amiπo-4-methyl-phenyl, 4-halo-phenyl, 4- formylamino-phenyl, 2-acetylamino-phenyl, 3-acetylamino-phenyl, 4-acetylamino- phenyl, N-3-phenyl-acetamide, N-4-phenyl-acetamide, N-4-phenyl-propionamide, N-4- pheπyl-isobutyramide, N-4-phenyl-acrylamide, N-4-phenyl-benzamide, 4-(N,N- dimethyl-sulfonyl-amino)-phenyl, N-4-phenyl-2,2,2-trifluoro-acetamide trifluoro acetic acid, 4-phenyl-cyclopropanecarboxylic acid amide, 4-phenyloxy, 3,5-dihalo-phenyloxy, phenyl-ethyπyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridyl-thiomethyl and/or 5- trifluoromethyl-2-pyridyl-thiomethyI.
In an eighth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, wherein one of R1 and R2 represents phenyl or naphthyl; and the other of R1 and R2 represents hydrogen.
In a ninth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, wherein both of X and Y represent CR2, CR3 or N, wherein R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; or X represents N or CR2, wherein R2 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and Y represents N or CR3, wherein R3 together with R1, and together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
In a tenth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula II,
Figure imgf000009_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein n is 1 , 2 or 3; and X represents CR4 or N, wherein R4 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl;
R1 and R2, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, phenyl, phenyloxy, heteroaryl and/or heteroaryloxy, which phenyl, phenyloxy, heteroaryl and heteroaryloxy may optionally be substituted one or two times with alkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, a group of the formula R'CONH-, R'S02NH- and/or (R'S02)2N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkeπyl, phenyl or benzyl; wherein R' represents hydrogen or alkyl; or
R1 and R2, together with the carbon atoms to which they are bound, form a benzo-fused aromatic benzene ring, which benzene ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
In a more preferred embodiment the diazabicyclic aryl derivative of the invention is a diazabicyclic aryl derivative of Formula II, wherein
R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halo, CF3, OCF3, CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4-methyl-phenyl, 3-nitro-phenyl, 4- πitro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-pheπyl, 2-haIo-5- trifluoromethyl-phenyl, 2-amiπo-phenyl, 2-amino-4-methyl-phenyl, 3-amino-phenyl, 4- amino-phenyl, 2-amino-4-methyl-phenyl, 4-halo-pheπyl, 4-formylamiπo-pheπyl, 2- acetylamino-phenyl, 3-acetylamino-phenyl, 4-acetylamino-phenyl, N-3-phenyl- acetamide, N-4-phenyl-acetamide, N-4-phenyl-propioπamide, N-4-phenyl- isobutyramide, N-4-phenyl-acrylamide, N-4-phenyl-benzamide, 4-(N,N-dimethyl- sulfonyl-amino)-phenyl, N-4~phenyl-2,2,2-trifluoro-acetamide trifluoro acetic acid, 4- phenyl-cyclopropanecarboxylic acid amide, 4-phenyloxy, 3,5-dihalo-phenyloxy, phenyl-ethynyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridyl-thiomethyl or 5-trifluoromethyl- 2-pyridyI-thiomethyl ;
R2 represents hydrogen or halo; and
R4 represents hydrogen, alkyl or halo.
In an eleventh preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula 111,
Figure imgf000011_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein π is 1 , 2 or 3; and
X represents CR4 or N, wherein R4 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy;
R5 and R6, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, ' cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy.
In a more preferred embodiment the diazabicyclic aryl derivative of the invention is a diazabicyclic aryl derivative of Formula III, wherein R4 rep resents hydrogen or alkyl; R5 represents hydrogen, alkyl or alkoxy; and R6 represents hydrogen, alkyl or alkoxy.
In a most preferred embodiment the diazabicyclic aryl derivative of the invention is
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-8-methoxy-benzofuran-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-benzofuran-2-yl-methanone; or
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-3-methyl-benzofuran-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-benzooxazol-2-yl-methanone; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
In a twelfth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, la, lb or II, wherein
R1 represents a group of formula -(alkyl)m-Z-aryl, -(alkyl)m-Z-heteroaryl or -C≡C-aryl, wherein m is 0 or 1; and Z represents O or S; and wherein the aryl and heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl.
In a thirteenth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I, la, lb or II, wherein R represents a group of formula -CH2- Z-phenyl, -CH2-Z-pyridyl or -C=C-phenyl, wherein m is 0 or 1; and Z represents O or S; and wherein the phenyl and pyridyl group may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl.
In a most preferred embodiment the diazabicyclic aryl derivative of the invention is
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3,5-dichlorophenoxy)-furan-2-yl- methanone;
(1,4-Diaza-bicyclof3.2.2]non-4-yl)-5-[5-(trifluoromethyl-2-pyridyl)- thiomethyl]-furan-2-yl-methanone; or
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-phenylethynyl-furan-2-yl-methanone; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
In a fourteenth preferred embodiment the invention provides a diazabicyclic aryl derivative of Formula I or II, wherein R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halo, CF3, OCF3, CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4- methyl-phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 3-trifluoromethyl-phenyl, 4- trifluoromethyl-phenyl, 2-halo-5-trifluoromethyl-phenyl, 2-amino-ρhenyl, 2-amino-4- methyl-phenyl, 3-amino-phenyl, 4-amiπo-phenyl, 2-amino-4-methyl-phenyl, 4-halo- phenyl, 4-formylamino-phenyl, 2-acetylamino-phenyl, 3-acetylamino-phenyl, 4- acetylamiπo-phenyl, N-3-phenyl-acetamide, N-4-phenyl-acetamide, N-4-phenyl- propionamide, N-4-phenyl-isobutyramide, N-4-phenyl-acrylamide, N-4-phenyl- benzamide, 4-(N,N-dimethyl-sulfonyl-amino)-pheπyl, N-4-phenyl-2,2,2-trifluoro- acetamide trifluoro acetic acid, 4-phenyl-cyclopropanecarboxylic acid amide, 4- phenyloxy, 3,5-dihalo-phenyloxy, phenyl-ethynyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyridyl-thiomethyl or 5-trifluoromethyl-2-pyridyl-thiomethyI;
R2 represents hydrogen, alkyl or halo; and
R3 represents hydrogen, alkyl or halo.
In a most preferred embodiment the diazabicyclic aryl derivative of the invention is
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-bromo-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-nitro-furaπ-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-(5-phenyl-furan-2-yl)-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-nitrophenyl)-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3-trifluoromethylpheπyl)-furan-2-yl- methaπone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone; (1,4-Diaza-bicycIo[3.2.2]non-4-yl)-5-(4-chlorophenyl)-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(2-nitrophenyl)-furan-2-yl-methanoπe;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3-nitrophenyl)-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-acetylaminophenyl)-furan-2-yl- methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(2-aminophenyl)-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3-aminophenyl)-furan-2-yl-methanone;
(1 ,4-Diaza-bicycIo[3.2.2]non-4-yl)-5-(2-acetylaminophenyl)-furan-2-yl- methanone
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3-acetylaminophenyl)-furan-2-yl- methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-3-methyl-furan-2-yl-methanone;
(1 ,4-Diaza-bicyclo[3.2.2]non-4-yl)-4,5-dibromo-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(2-chloro-5-trifluoromethylphenyl)- furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(2-nitro-4-methylphenyl)-furan-2-yl- methanone;
(1,4-Diaza-bicyclo[3.2.2]noπ-4-yl)-5-(2-amino-4-methylphenyl)-furan-2-yl- methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-[4-(N,N-dimethylsulfonyl)aminophenyl]- furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-formylaminophenyl)-furan-2-yl- methanone;
N-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- propionamide;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3,5-dichlorophenoxy)-furan-2-yl- methanoπe;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-[5-(trifluoromethyl-2-pyridyl)- thiomethyl]-furan-2-yl-methanone;
N-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- 2,2,2-trifluoro-acetamide trifluoro acetic acid;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-3-bromo-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-phenyIethynyl-furan-2-yl-methanone;
N-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- acrylamide;
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- benzamide;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-[4-(N,N-diphenylsulfonylamino)pheπyl]- furan-2-yl-methanone; N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan~2-yl]-phenyl}- isobutyramide;
Cyclopropanecarboxylic acid {4-[5-(1 ,4-diaza-bicyclo[3.2.2]nonane~4- carbonyl)-furaπ-2-yl]-phenyl}-amide;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone;
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]noπane-4-carbonyl)-furan-2-yl]-phenyl}- acrylamide N-oxide; or
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- acrylamide; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
Any combination of two or more of the embodiments described herein is considered within the scope of the present invention.
Definition of Substituents in the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to eighteen carbon atoms (Ci.is-alkyl), more preferred of from one to six carbon atoms (Cι_6-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a Chalky! group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a Cι_3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C^-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopeπtyl, cyclohexyl and cycloheptyl.
In the context of this invention a cycloalkyl-alkyl group designates a cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl group as also defined above. Examples of preferred cycloalkyl-alkyl groups of the invention include cyclopropylmethyl and cyclopropylethyl.
In the context of this invention an alkoxy group designates an "alkyl-O-" group, wherein alkyl is as defined above. Examples of preferred alkoxy groups of the invention include methoxy and ethoxy.
In the context of this invention a cycloalkoxy group designates a "cycloalkyl-O-" group, wherein cycloalkyl is as defined above.
In the context of this invention a cyano-alkyl group designates an alkyl group substituted with CN, wherein alkyl is as defined above.
In the context of this invention halo represents fluoro, chloro, bromo or iodo, and haloalkyl group designates an alkyl group as defined herein, which alkyl group is substituted one or more times with halo. Thus a trihalomethyl group represents e.g. a trifluoromethyl group, a trichloromethyl group, and similar trihalo- substituted methyl groups. Preferred haloalkyl groups of the invention include trihalogenmethyl, preferably CF3.
In the context of this invention a haloalkoxy group designates an alkoxy group as defined herein, which alkoxy group is substituted one or more times with halo. Preferred haloalkoxy groups of the invention include trihalogenmethoxy, preferably CF30-.
In the context of this invention an aryl group designates a monocyclic or polycyclic aromatic hydrocarbon group. Examples of preferred aryl groups of the invention include phenyl, indenyl, naphthyl, azulenyl, fluorenyl, and anthracenyl. The most preferred aryl group of the invention is phenyl.
In the context of this invention an aryloxy group designates an "aryl -0-" group, wherein aryl is as defined above. The most preferred aryloxy group of the invention is phenoxy.
In the context of this invention a heteroaryl group designates an aromatic mono- or polycyclic heterocyclic group, which holds one or more heteroatoms in its ring structure. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).
Preferred 5-6 membered heteroaryl groups of the invention include furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; selenophenyl, in particular selenophen-2- or 3-yl; pyrrolyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2, 4- or 5-yl; thiazolyl, in particular thiazol-2, 4- or 5-yl; imidazolyl, in particular imidazol-2- or 4-yl; pyrazolyl, in particular pyrazol-3- or 4-yl; isoxazolyl, in particular isoxazol-3, 4- or 5-yl; isothiazolyl, in particular isothiazol-3-, 4- or 5-yl; oxadiazolyl, in particular 1 ,2,3- oxadiazol-4- or 5-yl, or 1 ,3,4-oxadiazol-2-yl; triazolyl, in particular 1 ,2,3-triazol-4-yl or 1 ,2,4-triazol-3-yl; thiadiazolyl, in particular 1 ,2,3-thiadiazol-4- or 5-yl, or 1,3,4- thiadiazol-2-yl; pyridyl, in particular pyrid-2-, 3- or 4-yl; pyridazinyl, in particular pyridazin-3- or 4-yl; pyrimidinyl, in particular pyrimidiπ-2-, 4- or 5-yl; pyrazinyl, in particular pyrazin-2- or 3-yl; and triazinyl, in particular 1 ,2,4- or 1 ,3,5-triazinyl.
More preferred 5 membered heteroaryl groups of the invention include furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; pyrrolyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2, 4- or 5-yl; thiazolyl, in particular thiazol-2, 4- or 5-yl; isoxazolyl, in particular isoxazol-3, 4- or 5- yl; isothiazolyl, in particular isothiazol-3-, 4- or 5-yl; and thiadiazolyl, in particular 1 ,2,3-thiadiazol-4- or 5-yl, or 1,3,4-thiadiazol-2-yl.
Most preferred 5 membered heteroaryl groups of the invention include furanyl, in particular furan-2- or 3-yl; and thienyl, in particular thien-2- or 3-yl. More preferred 6 membered heteroaryl groups of the invention include pyridyl, in particular pyrid-2-, 3- or 4-yl; and pyrazinyl, in particular pyrazin-2- or 3-yl.
In the context of this invention an aromatic bicyclic heterocyclic group designates a bicyclic heterocyclic group, which holds one or more heteroatoms in its ring structure. In the context of this invention the term "bicyclic heterocyclic group" includes benzo-fused five- and six-membered heterocyclic rings containing one or more heteroatoms. Preferred heteroatoms include nitrogen (N), oxygen (O), and sulphur (S).
Preferred bicyclic heteroaryl groups of the invention include indoliziπyl, in particular indoIizin-2-, 5- or 6-yl; indolyl, in particular indol-2-, 5- or 6-yl; isoindolyl, in particular isoindol-2-, 5- or 6-yl; benzo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; beπzo[b]thienyl, in particular benzothien-2-, 5- or 6-yl; benzoimidazolyl, in particular benzoimidazol-2-, 5- or 6-yl; benzothiazolyl, in particular benzothiazol-5- or 6-yl; purinyl, in particular purin-2- or 8-yl; quinolinyl, in particular quinolin-2-, 3-, 6- or 7-yl; isoquinolinyl, in particular isoquinolin-3-, 6- or 7-yl; cinnolinyl, in particular cinnolin-6- or 7-yl; phthalazinyl, in particular phthalaziπ-6- or 7-yl; quinazolinyl, in particular quinazolin-2-, 6- or 7-yl; quinoxalinyl, in particular quinoxalin-2- or 6-yl; 1 ,8-naphthyridinyl, in particular 1,8-naphthyridin-2-, 3-, 6- or 7-yl; and pteridinyl, in particular pteridin-2-, 6- or 7-yl.
More preferred bicyclic heteroaryl groups of the invention include indolyl, in particular indol-2-, 5- or 6-yl; benzo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; benzo[b]thienyl, in particular benzothien-2-, 5- or 6-yl; benzoimidazolyl, in particular benzoimidazol-2-, 5- or 6-yl; and quinoxalinyl, in particular quinoxalin-2- or 6-yl.
Most preferred bicyclic heteroaryl groups of the invention include indolyl, in particular indol-2-, 5- or 6-yl; beπzo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; benzo[b]thienyl, in particular benzothien-2-, 5- or 6-yl.
In the context of this invention a heteroaryloxy group designates a "heteroaryl-0-" group, wherein heteroaryl is as defined above.
Pharmaceutically Acceptable Salts
The diazabicyclic aryl derivative of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzensulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulphonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphtalene-2-sulphonic acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphonic acid, and the like. Such salts may be formed by procedures well known and described in the art.
Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
Metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.
Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysine, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art.
In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts (aza-onium salts). Preferred aza-onium salts include the alkyl-onium salts, in particular the methyl- and the ethyl-onium salts; the cycloalkyl-onium salts, in particular the cyclopropyl-onium salts; and the cycloalkylalkyl-oπium salts, in particular the cyclopropyl-methyl-onium salts.
Particularly preferred onium salts of the invention include those created at the N' position according to the following Formula I'
Figure imgf000018_0001
Steric Isomers
The chemical compounds of the present invention may exist in (+) and (-) forms as well as in racemic forms. The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.
Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or I- (tartrates, mandelates, or camphorsulphoπate) salts for example.
The chemical compounds of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the chemical compound of the present invention with an optically active chloroformate or the like.
Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in "Enantiomers. Racemates. and Resolutions". John Wiley and Sons, New York (1981).
Optical active compounds can also be prepared from optical active starting materials.
Methods of Producing Diazabicyclic Aryl Derivatives
The diazabicyclic aryl derivative of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals. Also one compound of the invention can be converted to another compound of the invention using conventional methods.
The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
Biological Activity
The present invention is devoted to the provision novel ligands and modulators of the nicotinic receptors, which ligands and modulators are useful for the treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine receptor (nAChR). Preferred compounds of the invention show a pronounced nicotinic acetylcholine al receptor subtype selectivity.
The compounds of the present invention may in particular be agonists, partial agonists, antagonists and/or allosteric modulators of the nicotinic acetylcholine receptor.
Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
The compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for in vivo receptor imaging (neuroimagiπg), and they may be used in labelled or uπlabelled form.
In a preferred embodiment the compounds of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system. Such diseases or disorders includes anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder (ADHD), Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, psychosis, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post- traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag. In a preferred embodiment diseases, disorders, or conditions relating to the central nervous system for which the compounds of the invention are used are cognitive disorders, psychosis, schizophrenia and/or depression.
In another preferred embodiment the compounds of the invention may be useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
In yet another preferred embodiment the compounds of the invention may be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
In still another preferred embodiment the compounds of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.
In even another preferred embodiment the compounds of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.
In still another preferred embodiment the compounds of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain. The pain may in particular be neuropathic pain, chronic headache, central pain, pain related to diabetic neuropathy, to post therapeutic neuralgia, or to peripheral nerve injury.
Finally the compounds of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.
In this context "treatment" covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a voluntary diminished intake of the addictive substance.
In another aspect, the compounds of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various tissues. Pharmaceutical Compositions
In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the diazabicyclic aryl derivative of the invention.
While a chemical compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
In a preferred embodiment, the invention provides pharmaceutical compositions comprising the diazabicyclic aryl derivative of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic and/or prophylactic ingredients, know and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
The pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy. Preferred routes of administration include oral administration, in particular in tablet, in capsule, in drage, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition of the invention can be manufactured by the skilled person by use of standard methods and conventional techniques appropriate to the desired formulation. When desired, compositions adapted to give sustained release of the active ingredient may be employed.
The diazabicyclic aryl derivative of the invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
When desired, compositions adapted to give sustained release of the active ingredient may be employed.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).
A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g. ED50 and LD50, may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LDβo EDso. Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
The actual dosage depend on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 μg/kg i.v. and 1 μg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 μg/kg to about 10 mg/kg/day i.v., and from about 1 μg/kg to about 100 mg/kg/day p.o.
Methods of Therapy
The diazabicyclic aryl derivatives of the present invention are valuable nicotinic receptor modulators, and therefore useful for the treatment of a range of ailments involving cholinergic dysfunction as well as a range of disorders responsive to the action of nAChR modulators.
In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a diazabicyclic aryl derivative of the invention. In the context of this invention the term "treatment" covers treatment, prevention, prophylaxis or alleviation, and the term "disease" covers illnesses, diseases, disorders and conditions related to the disease in question.
The preferred indications contemplated according to the invention are those stated above.
It is at present contemplated that suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o. The upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.
EXAMPLES
The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.
Example 1 Preparatory Example
All reactions involving air sensitive reagents or intermediates were performed under nitrogen and in anhydrous solvents.
1.4-Diazabicvclor3.2.21πonan-3-one (Intermediate compound^
32.33 g (200 mmol) of 3-Quinuclidinone hydrochloride was dissolved in 75 ml of water, and to the solution of hydroxylamine hydrochloride (16.4 g; 236 mmol) and CH3C02Na • 3H20 (80 g; 588 mmol) was added. The mixture was stirred at 70°C for 1 hour. Then NaCI (10 g) was dissolved in the mixture and was cooled to 0°C. Separated crystals were filtered and carefully dried. The obtained crude 3- quinuclidone oxime (approx. 30 g) was used in the next step of the synthesis without further purification.
Polyphosphoric acid (180 g) of was heated to 100°C and crude 3- quinuclidone oxime (30 g) was added portionwise. The reaction mixture was heated at 130°C for 20 minutes. The mixture was cooled to room temperature, and 50 ml of water was added. The mass was carefully homogenised, the mixture was poured into of ice (100 g). The mixture was made alkaline (pH 12) by adding sodium hydroxide. The mixture was extracted with chloroform (2 x 400 ml). The extract was dried over sodium sulphate and the solvent was removed under reduced pressure.
Yield of the mixture of the products 1 ,4-diazabicyclo[3.2.2]nonan-3-one and 1,3-diazabicyclo[3.2.2]nonan-4-one was 19.02 g (68%). The mixture of isomers was crystallized from 80 ml of dioxaπe to yield 1,4-diazabicyclo[3.2.2]nonan-3-one (5.12 g; 18%). The solvent from filtrate was distilled off, flash chromatography (with acetone) of the residue gave of 1,3-diazabicyclo[3.2.2]nonan-4-one (8.91 g 32%).
1.4-Diazabicvclor3.2.21nonane TJ. Med. Chem. 1993362311-23201 (Intermediate compound)
1,4-Diazabicyclo[3.2.2]nonan-3-one (5.12 g; 36 mmol) was dissolved in tetrahydrofuran (50 ml), litium aluminium hydride 2.28 g (60 mmol) was added to the solution and the reaction mixture was refluxed for 36 hours. After cooling the reaction mixture to room temperature, water (2.3 ml) was added dropwise and the mixture was filtered. The solvent was removed from the filtrate by rotavapor at reduced pressure. The formed substance was distilled with Kugelrohr (0.5 mBar, 70°C). Yield of the title compound 3.11 g (68%).
3-Bromo-2-furoic acid (Intermediate compound)
To a mixture of 3-bromo furan (51.0 g; 0.347 mol) and THF (250 ml) was added lithiumdiisopropylamide (191 ml; 0.382 mol; 2M solution in heptane / THF / ethylbenzene) at -70°C. The mixture was stirred for 1 hour at -70°C. Solid carbondioxide (100.3 g; 2.28 mol) was added and the mixture was stirred until the carbondioxide was gone. Water (50 ml) was added followed by aqueous hydrochloric acid (380 ml; 2M). The tetrahydrofuran was evaporated. The mixture was extracted with diethylether (3 x 100 ml). The combined ether phase was extracted with aqueous sodium hydroxide (3 x 100 ml; 2M). The aqueous phase was cooled on ice and acidified with aqueous hydrochloric acid (100 ml; 10M). The mixture was extracted with ether (3 x 100 ml). The combined ether phase was evaporated. Yield 36 g (54%). Mp. 118.5°C.
Method A
(1.4-Diaza-bicvclor3.2.21non-4-yl)-furan-2-yl-methaπone hydrochloric acid salt
(Compound A1 )
A mixture of 1 ,4-Diaza-bicyclo[3.2.2]nonane (0.50 g; 4.0 mmol), 2-furoyl chloride (0.52 mg; 4.0 mmol), diisopropylethylamine (1.02 g; 7.9 mmol) and 1,2- dimethoxyethaπe (25 ml) was stirred at room-temperatue over night. The product precipitated as hydrochloric acid salt and was filtered and washed with 1 ,2- dimethoxyethaπe (5 ml). Yield 0.84 g (82%). Mp. 279-283°C. (1.4-Diaza-bicvclor3.2.21non-4-yl)-5-bromo-furan-2-yl-methanone fumaric acid salt (Compound A2)
The title compound was prepared according to Method A, from 5-bromo-2- furoyl chloride (Method B) using no diisopropylethylamine. Aqueous sodium hydroxide (10 ml; 1M) was added. The mixture was extracted with dichloromethane (3 x 10 ml). Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Mp. 192.7- 196.4°C.
(1.4-Diaza-bicvclo[3.2.21non-4-yl)-5-nitro-furan-2-yl-methanone hydrochloric acid salt (Compound A3)
The title compound was prepared according to Method A, from 5-nitro-2- furoyl chloride (Method B), using no diisopropylethylamine. Mp. 242.6-251.0°C.
(1.4-Diaza-bicvclor3.2.21non-4-yl)-5-(4-nitrophenyl)-furan-2-yl-methanoπe hydrochloric acid salt (Compound A4)
The title compound was prepared according to Method A from 5-(4- nitrophenyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 298.2°C.
(1.4-Diaza-bicvclor3.2.2lnon-4-yl)-5-(3-trifluoromethylphenyl)-furaπ-2-yl-methanone hydrochloric acid salt (Compound A5)
The title compound was prepared according to Method A from 5-(3- trifluoromethylpheπyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 236.9°C.
(1.4-Diaza-bicyclor3.2.2lnon-4-yl)-5-(4-chlorophenyl)-furan-2-yl-methanone hydrochloric acid salt (Compound A6)
The title compound was prepared according to Method A from 5-(4- chlorophenyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 272.5-274.7°C.
(1.4-Diaza-bicvclor3.2.21non-4-yl)-5-(2-πitrophenyl)-furan-2-yl-methanone hydrochloric acid salt (Compound A7)
The title compound was prepared according to Method A from 5-(2- nitrophenyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 216.3- 219.9°C. (1.4-Diaza-bicvclor3.2.2lπon-4-ylV5-(3-nitrophenyl)-furan-2-yl-methaπoπe hydrochloric acid salt (Compound A8)
The title compound was prepared according to Method A from 5-(3- nitrophenyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 224- 230°C.
(1.4-Diaza-bicvclor3.2.2lπoπ-4-yl)-8-methoxy-benzofuran-2-yl-methanone hydrochloric acid salt (Compound A9)
The title compound was prepared according to Method A from 8-methoxy-2- benzofuroyl chloride (Method B), using no diisopropylethylamine. Mp. 241 -246°C.
(1.4-Diaza-bicvclor3.2.21non-4-vO-oxazolyl-5-yl-methanone hydrochloric acid salt (Compound A10)
The title compound was prepared according to Method A from 5-oxazoloyl chloride (Method B), using no diisopropylethylamine. Mp. >160°C (decomp.).
(1 ,4-Diaza-bicvclor3.2.21non-4-yl)-benzofuran-2-yl-methanone hydrochloric acid salt (Compound A11)
The title compound was prepared according to Method A from 2- beπzofuroyl chloride (Method B), using no diisopropylethylamine. Mp. 264 °C.
(1.4-Diaza-bicvclor3.2.21πon-4-yl)-3-methyl-furan-2-yl-methanone hydrochloric acid salt (Compound A12)
The title compound was prepared according to Method A from 3-methyI-2- furoyl chloride (Method B), using no diisopropylethylamine. Mp. 225.8-227.2°C.
(1.4-Diaza-bicvclor3.2.21πon-4-yl)-4.5-dibromo-furan-2-yl-methanone fumaric acid salt (Compound A13)
The title compound was prepared according to Method A from 4,5-dibromo- 2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 250.9-254.3°C.
(1.4-Diaza-bicvclor3.2.21non-4-yl)-5-(2-chloro-5-trifluoromethylphenyl)-furan-2-yl- methaπone hydrochloric acid salt (Compound A14)
The title compound was prepared according to Method A from 5-(2-chloro- 5-trifluoromethylphenyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 201 °C. (1.4-Diaza-bicvclor3.2.21non-4-yl)-5-(2-nitro-4-methylphenyl)-furaπ-2-yl-methanone hydrochloric acid salt (Compound A15)
The title compound was prepared according to Method A from 5-(2-nitro-4- methylphenyl)-2-furoyl chloride (Method B), using no diisopropylethylamine. Mp. 199°C.
(1.4-Diaza-bicvclor3.2.21non-4-yl)-3-methyl-benzofuran-2-yl-methanone hydrochloric acid salt (Compound A16)
The title compound was prepared according to Method A from 3-methyl-2- beπzofuroyl chloride (Method B), using no diisopropylethylamine. Mp. 260-276°C.
(1.4-Diaza-bicvclor3.2.2lnon-4-vπ-5-phenyl-1 ,3.4-oxadiazol-2-yl-methanone hydrochloric acid salt (Compound A17)
The title compound was prepared according to Method A from 5-methyI- 1 ,3,4-oxadiazol-2-carbonyl-chloride chloride, using no diisopropylethylamine. Mp. 280-290°C.
(1.4-Diaza-bicvclor3.2.21πon-4-yl)-5-(3.5-dichlorophenoxy)-furan-2-yl-methanone hydrochloric acid salt (Compound A18)
The title compound was prepared according to Method A from 5-(3,5- dichlorophenoxy)-furan-2-carbonyl chloride, using no diisopropylethylamine. Mp. 124°C.
(1.4-Diaza-bicvclor3.2.2lnon-4-yl)-5-r5-(trifluoromethyl-2-pyridyl)-thiomethyll-furan-2- yl-methanone hydrochloric acid salt (Compound A19)
The title compound was prepared according to Method A from 5-[5- (trifluoromethyl-2-pyridyl)-thiomethyl]-furan-2-carbonyl chloride, using no diisopropylethylamine. Mp. 176°C.
(1.4-Diaza-bicvclor3.2.21non-4-yl)-3-bromo-furaπ-2-yl-methanone fumaric acid salt (Compound A20)
The title compound was prepared according to Method A, from 3-bromo-2- furoyl chloride (Method B from 3-bromo-2-furoic acid) using no diisopropylethylamine. Mp. 157.4-159.9°C. (1.4-Diaza-bicvclor3.2.21non-4-yl)-5-phenylethynyl-furan-2-yl-methanone fumaric acid salt (Compound A21 )
The title compound was prepared according to Method A, from 5-(2- phenylethyπyl)-2-furanoic acid chloride. Mp. 166.3-168.3°C.
Method B
3-Bromo-2-furoic acid (Intermediate compound)
To a mixture of 3-bromo furan (51.0 g; 0.347 mol) and THF (250 ml) was added lithiumdiisopropylamide (191 ml; 0.382 mol; 2 M solution in heptane / THF / ethylbenzene) at -70°C. The mixture was stirred for 1 hour at -70°C. Solid carbondioxide (100.3 g; 2.28 mol) was added and the mixture was stirred until the carbondioxide was gone. Water (50 ml) was addded followed by aqueous hydrochloric acid (380 ml; 2M). The tetrahydrofuran was evaporated. The mixture was extracted with diethyiether (3 x 100 ml). The combined ether phase was extracted with aqueous sodium hydroxide (3 x 100 ml; 2M). The aqueous phase was cooled on ice and acidified with aqueous hydrochloric acid (100 ml; 10M). The mixture was extracted with ether (3 x 100 ml). The combined ether phase was evaporated. Yield 36 g (54%). Mp. 118.5°C.
5-(4-nitrophenyl)-2-furoyl chloride (Intermediate Compound)
The title compound was prepared by stirring a mixture of 5-(4-nitrophenyl)- 2-furoic acid (1.0 g; 4.3 mmol) and thionyl chloride (10 ml) at reflux for 2 hours. The mixture was evaporated and co-evaporated with anhydrous toluene. The acid chloride was used without further purification.
Method C
(1.4-Diaza-bicvclor3.2.2lnon-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone fumaric acid salt (Compound C1 )
A mixture of (1 ,4-diaza-bicyclo[3.2.2]non-4-yl)-5-(4-πitrophenyl)-furan-2-yl- methanoπe (0.70 g; 1.9 mmol), palladium on carbon (400 mg; 5%) and ethanol (30 ml) was stirred under hydrogen for 24 hours. The mixture was filtered through celite and evaporated. Yield 0.44 g (74%). The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1 ) saturated with fumaric acid. Mp. 227.8°C.
(1.4-Diaza-bicvclof3.2.21non-4-yl)-5-(2-aminophenyl)-furan-2-yl-methanoπe fumaric acid salt (Compound C2)
The title compound was prepared according to Method C from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(2-nitrophenyl)-furan-2-yl-methanone. Mp. 201.1 -207.3°C. (1,4-Diaza-bicvcior3.2.2lnon-4-yl)-5-(3-aminophenyl)-furan-2-yl-methaπone fumaric acid salt (Compound C3)
The title compound was prepared according to Method C from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(3-nitrophenyl)-furan-2-yl-methanone. Mp. 184.9-188.2°C.
(1,4-Diaza-bicyclor3.2.2lnon-4-yl)-5-(2-amino-4-methylpheπyl)-furan-2-yl-methanone fumaric acid salt (Compound C4)
The title compound was prepared according to Method C from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(2-nitro-4-methylphenyl)-furan-2-yl-methanone. Mp. 179°C.
Method D
(1,4-Diaza-bicvclor3.2.2lnon-4-yl)-5-(4-acetylaminopheπyl)-furan-2-yl-methanone (Compound D1)
Acetic acid anhydride (133 mg; 1.3 mmol) solved in dichloromethane (2 ml) was added dropwise to a mixture of (1 ,4-diaza-bicyclo[3.2.2]non-4-yl)-5-(4- aminophenyl)-furan-2-yl-methanone and dichloromethane (10 ml) at room temperature. The mixture was allowed to stir for 4 hours. Aqueous sodium hydroxide (20 ml; 1M) was added followed by extraction with dichloromethane (3 x 20 ml). The crude mixture was purified by silica gel chromatography, using a mixture of dichloromethane : methanol (4:1) and 2% methanol as eluent. The product was isolated as the free base. Mp. 113°C (decomp.).
(1,4-Diaza-bicyclor3.2.2lnon-4-yl)-5-(2-acetylaminophenyl)-furan-2-yl-methanone fumaric acid salt (Compound D2)
The title compound was prepared according to Method D from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(2-aminophenyl)-furan-2-yl-methanone. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Mp. 178.9-185.0°C.
(1,4-Diaza-bicvclor3.2.2lnon-4-yl)-5-(3-acetylaminophenyl)-furan-2-yl-methanone fumaric acid salt (Compound D3)
The title compound was prepared according to Method D from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(3-aminophenyl)-furan-2-yl-methanone. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1 ) saturated with fumaric acid. Mp. 216°C.
Λ/-{4-r5-(1.4-Diaza-bicvclor3.2.21nonane-4-carbonyl)-furaπ-2-yl1-phenyl)-propionamide free base (Compound D4)
The title compound was prepared according to Method D from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone. Mp. 264°C. Λ/-(4-r5-(1.4-Diaza-bicvclof3.2.21πonane-4-carboπyl)-furaπ-2-vπ-phenyl -2.2.2-trifluoro- acetamide trifluoro acetic acid salt (Compound D5)
The title compound was prepared according to Method D from (1,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone and trifluoroacetic anhydride. Mp. 219°C.
Λ/-f4-r5-(1.4-Diaza-bicvclor3.2.21nonane-4-carboπyl)-furan-2-vn-phenyl>-isobutyramide fumaric acid salt (Compound D6)
The title compound was prepared according to Method D from (1 ,4-diaza- bicycIo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone and isobutyric anhydride. Mp. 223°C.
Method E
(1.4-Diaza-bicvclor3.2.2lnon-4-yl)-5-r4-(Λ/.A/-dimethylsulfonyl)aminophenvπ-furan-2-yl- methanone free base (Compound ED
A mixture of (1 ,4-diaza-bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2- yl-methanone (0.5 g; 1.6 mmol) and dichloromethane (5 ml), methanesulfonyl chloride (2.12 g; 18.4 mmol) and dichloromethane (5 ml) was stirred at room temperature for 15 hours. Aqueous sodium hydroxide (5 ml; 1M) was added followed by extraction with dichloromethane (3 x 5 ml). The crude mixture was purified by silica gel chromatography, using a mixture of dichloromethane : methanol (9:1) and 1% methanol as elueπt. The product was isolated as the free base. Yield 20 mg (3%). Mp. 189°C.
A-f4-r5-(1,4-Diaza-bicvclor3.2.2lπonane-4-carbonyl)-furan-2-vn-phenyl)-acrylamide fumaric acid salt (Compound E2)
The title compound was prepared according to Method E from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone and acryloyl chloride (1.6 eq.). Mp. 220°C.
Λ/-(4-r5-(1,4-Diaza-bicvclor3.2.2lπohaπe-4-carbonyl)-furaπ-2-yll-pheπyl)-benzamide fumaric acid salt (Compound E3)
The title compound was prepared according to Method E from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone, diisopropylethylamine (2 eq.) and benzoyl chloride (1.5 eq.). Mp. 254 °C.
(1.4-Diaza-bicvclor3.2.2lnon-4-yl)-5-r4-(Λ/.Λ/-diphenylsulfoπylamino)phenvn-furan-2-yl- methanone fumaric acid salt (Compound E4)
The title compound was prepared according to Method E from (1 ,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(4-amiπophenyl)-furan-2-yl-methanone, diisopropylethylamine (2 eq.) and beπzenesulfonyl chloride (1.5 eq.). Mp. 201 -203°C. Cvclopropanecarboxylic acid (4 5-(1.4-diaza-bicvclor3.2.21nonane-4-carbonyl)-furan- 2-vπ-phenyll-amide fumaric acid salt (Compound E5)
The title compound was prepared according to Method E from (1,4-diaza- bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone, cyclopropanecarbonyl chloride. Mp. 254°C.
Method F
(1.4-Diaza-bicvclor3.2.2lπon-4-yl)-5-(4-formylaminophenyl)-furan-2-yl-methanone (Compound F1)
A mixture of (1 ,4-diaza-bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2- yl-methanone (0.50 g; 1.6 mmol) and ethylformate (30 ml) was stirred at reflux for 9 days. The mixture was evaporated. Aqueous sodium hydroxide (20 ml; 1M) was added followed by extraction with dichloromethane (3 x 20 ml). The crude mixture was purified by silica gel chromatography, using a mixture of dichloromethane : methanol (9:1 ) and 1% methanol as eluent. The product was isolated as the free base. Yield 0.29 g (53%). Mp. 236°C.
Method G
(1 ,4-Diaza-bicvclor3.2.21non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methaπoπe chloromethylium chloride salt (Compound GD
Ethylisothiocyaπate (182 mg; 2.09 mmol) solved in dichloromethane (20 ml) was added dropwise to a mixture of (1,4-diaza-bicyclo[3.2.2]non-4-yl)-5-(4- aminophenyl)-furan-2-yl-methanoπe and dichloromethane (10 ml) at 5°C. The mixture was allowed to stir for 4 hours at 5°C and 11 hours at room temperature. The solvent volume was reduced to a third and the solid product was isolated by filtration. Mp. >300°C.
Method H v-f4-r5-(1.4-Diaza-bicvclor3.2.21nonane-4-carbonyl)-furan-2-vn-phenyl -acrylamide methylium iodide (Compound HP
A mixture of Λ-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]noπane-4-carbonyl)-furan-2- yl]-phenyl}-acrylamide (175 mg; 0.479 mmol) and dichloromethane (10 ml) was stirred at -70°C. lodomethane (68 mg (0.479 mmol) solved in dichloromethane (5 ml) was added. The mixture was allowed to stir at -70°C for 1 hour. The mixture was allowed to reach room temperature and was evaporated and triturated with diethyiether. Yield 0.15 g (62%). Mp. 230-246°C. Method I
Λ/-f4-r5-(1.4-Diaza-bicvclor3.2.21πonane-4-carbonyl)-furan-2-vn-phenyl)-acrylamide N-oxide (Compound ID
A mixture of Λ/-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2- yl]-phenyl}-acrylamide (175 mg; 0.479 mmol), m-chloroperoxybenzoic acid (165 mg; 0.958 mmol) and dichloromethane (5 ml) was stirred at room-temperature for 15 hours. The crude mixture was evaporated. Chromatography on silica gel with dichloromethane, methanol and cone, ammonia (89:10:1) gave the title compound. Yield 180 mg (99%). Mp. 162°C.
Example 2
In vitro Inhibition of 3H-α-Bungarotoxine Binding in Rat Brain
In this example the affinity of the compounds of the invention for binding to oty-subtype of nicotinic receptors is determined. α-Bungarotoxine is a peptide isolated from the venom of the Elapidae snake Bungarus muiticinctus. It has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist. 3H-α-Bungarotoxine labels nicotinic acetylcholine receptors formed by the subunit isoform found in brain and the oil isoform in the neuromuscular junction.
Tissue preparation
Preparations are performed at 0~4°C. Cerebral cortices from male Wistar rats (150-250 g) are homogenised for 10 seconds in 15 ml of 20 mM Hepes buffer containing 118 mM NaCI, 4.8 mM KCI, 1.2 mM MgS04 and 2.5 mM CaCI2 (pH 7.5) using an Ultra-Turrax homogeniser. The tissue suspension is subjected to centrifugation at 27,000 x g for 10 minutes. The supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 minutes in 20 ml of fresh buffer, and the final pellet is then re-suspended in fresh buffer containing 0.01% BSA (35 ml per g of original tissue) and used for binding assays.
Assay
Aliquots of 500 μl of homogeπate are added to 25 μl of test solution and 25 μl of 3H-α-bungarotoxine (2 nM, final concentration) and mixed and incubated for 2 hours at 37°C. Non-specific binding is determined using (-)-nicotiπe (1 mM, final concentration). After incubation, the samples are added 5 ml of ice-cold Hepes buffer containing 0.05% PEI and poured directly onto Whatman GF/C glass fibre filters (pre- soaked in 0.1% PEI for at least 6 hours) under suction, and immediately washed with 2 x 5 ml ice-cold buffer. The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.
The test value is given as an IC50 (the concentration of the test substance which inhibits the specific binding of 3H-α-bungarotoxin by 50%).
The results of these experiments are presented in Table 1 below.
Table 1
Inhibition of 3H-α-Buπqarotoxine Binding
Figure imgf000033_0001

Claims

1. A Formula I
Figure imgf000034_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein
n is 1 , 2 or 3; and
X and Y, independently of one another, represents CR2, CR3 and/or N, wherein R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, aryl-alkyl, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, aryl-alkyl, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl or heteroaryl, which aryl or heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'SO∑NH- or (R'S02)2N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkenyl, phenyl or benzyl; or a group of formula aryl-alkyl-, aryl-Z-(alkyl)m-, aryl-C≡C-, heteroaryl- Z-(alkyl)m- or heteroaryl -C≡C-, wherein m is O or 1; and Z represents O or S; and wherein the aryl and heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl; or R1 and R2, or R1 and R3, together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
2. The diazabicyclic aryl of claim 1 , wherein n is 1 , 2 or 3.
3. The diazabicyclic aryl derivative of either one of claims 1 -2, wherein aryl is selected from the group consisting of phenyl, indenyl and naphthyl; and heteroaryl represents an aromatic 5- and 6-membered monocyclic heterocyclic group selected from the group consisting of furanyl, in particular furan-2- or 3-yl; thienyl, in particular thien-2- or 3-yl; pyrrolyl (azolyl), in particular pyrrol-2- or 3-yl; oxazolyl, in particular oxazol-2-, 4- or 5-yl; imidazolyl, in particular imidazol-2- or 4-yl; pyrazolyl, in particular pyrazol-1-, 3- or 4-yl; isoxazolyl, in particular isoxazol-3-, 4- or 5-yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl, thiadiazolyl, in particular 1,3,4- thiadiazol-2-yl, pyridyl, in particular pyrid-2-, 3- or 4-yl; pyridazinyl, in particular pyridazin-3- or 4-yl; pyrimidinyl, in particular pyrimidin-2-, 4- or 5-yl; and pyrazinyl, in particular pyrazin-2- or 3-yl; or an aromatic bicyclic heterocyclic group the group consisting of indolyl, in particular indol-2-, 3-, 5- or 6-yl, beπzo[b]furanyl, in particular benzofuran-2-, 5- or 6- yl; beπzo[b]thienyl, in particular benzothien-2-, 5- or6-yI; benzoimidazolyl, in particular benzoimidazol-2-, 5- or 6-yl; quinolinyl, in particular quinolin-2-, 3-, 6- or 7-yl; isoquinolinyl, in particular isoquinoliπ-3-, 6- or 7-yl; and cinnolinyl, in particular ciπnoIin-6- or7-yl.
4. The diazabicyclic aryl derivative of either one of claims 1-2, wherein
aryl represents phenyl;
aryl-alkyl represents benzyl; and
heteroaryl represents furanyl, in particular furan-2- or 3-yl; imidazolyl, in particular imidazol-2- or 4-yl; isoxazolyl, in particular isoxazol-3-, 4- or 5-yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl, thiadiazolyl, in particular 1,3,4-thiadiazol-2-yl, pyridyl, in particular pyrid-2-, 3- or 4-yl; or indolyl, in particular indol-2-, 3-, 5- or 6-yl.
5. The diazabicyclic aryl derivative of any one of claims 1 -4, wherein at least one of X and Y represents N; and the other of X and Y represent CR2; and π, R1 and R2 are as defined in claim 1.
6. The diazabicyclic aryl derivative of claim 5, which is (1,4-Diaza-bicyclo[3.2.2]non-4-yl)-oxazolyl-5-yl-methanone; (1,4-Diaza-bicycIo[3.2.2]non-4-yl)-(5-phenyl-oxazol-5-yl)-methanone; or (1,4-Diaza-bicycIo[3.2.2]non-4-yl)-5-phenyl-1,3,4-oxadiazol-2-yl- methanone; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
7. The diazabicyclic aryl derivative of any one of claims 1 -4, wherein one or two of R2 and R3, independently of one another, represent hydrogen and/or halo; and
R1 and the remainder of R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, halo, CF3, OCF3, CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4-methyl-phenyl, 3-nitro-phenyl, 4-nitro-phenyl, 3- trifluoromethyl-phenyl, 4-trifluoromethyl-pheπyl, 2-halo-5-trifluoromethyl-phenyl, 2- amino-phenyl, 2-amino-4-methyl-phenyl, 3-amino-phenyl, 4-amino-phenyl, 2-amino-4- methyl-phenyl, 4-halo-phenyl, 4-formylamino-phenyl, 2-acetylamino-phenyl, 3- acetylamino-phenyl, 4-acetylamino-phenyl, N-3-phenyl-acetamide, N-4-phenyl- acetamide, N-4-pheπyl-propioπamide, N-4-phenyl-isobutyramide, N-4-phenyl- acrylamide, N-4-phenyl-benzamide, 4-(N,N-dimethyl-sulfonyl-amino)-phenyl, N-4- pheπyl-2,2,2-trifluoro-acetamide trifluoro acetic acid, 4-pheπyl-cyclopropanecarboxylic acid amide, 4-phenyloxy, 3,5-dihalo-phenyloxy, phenyl-ethynyl, 2-pyridyI, 3-ρyridyl, 4- pyridyl, 2-pyridyl-thiomethyl and/or 5-trifluoromethyl-2-pyridyl-thiomethyl.
8. The diazabicyclic aryl derivative of any one of claims 1 -4, wherein both of X and Y represent CR2, CR3 or N, wherein R2 and R3, independently of one another, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl and/or heteroaryloxy, which aryl, aryloxy, heteroaryl and heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; or
X represents N or CR2, wherein R2 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; and
Y represents N or CR3, wherein R3 together with R1, and together with the carbon atoms to which they are bound, form a benzo-fused aromatic carbocyclic ring, which benzo-fused aromatic carbocyclic ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
9. The diazabicyclic aryl derivative of any one of claims 1 -4, represented by
Formula II
Figure imgf000037_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein
n is 1 , 2 or 3; and
X represents CR4 or N, wherein R4 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl; R1 and R2, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, phenyl, phenyloxy, heteroaryl and/or heteroaryloxy, which phenyl, phenyloxy, heteroaryl and heteroaryloxy may optionally be substituted one or two times with alkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, a group of the formula R'CONH-, R'S02NH- and/or (R'S02)2N-, wherein R' represents hydrogen, alkyl, cycloalkyl, haloalkyl, alkenyl, phenyl or benzyl; wherein R' represents hydrogen or alkyl; or
R1 and R2, together with the carbon atoms to which they are bound, form a benzo-fused aromatic benzene ring, which benzene ring may optionally be substituted one or two times with alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy, which aryl, aryloxy, heteroaryl or heteroaryloxy may optionally be substituted one or two times with halo, haloalkyl, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, wherein R' represents hydrogen or alkyl.
10. The diazabicyclic aryl derivative of claim 9, wherein
R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halo, CF3, OCF3, CN, nitro, phenyl, 2-πitro-phenyl, 2-nitro-4-methyl-phenyl, 3-nitro-phenyl, 4- nitro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-halo-5- trifluoromethyl-phenyl, 2-amino-phenyl, 2-amino-4-methyl-phenyl, 3-amino-phenyl, 4- amino-phenyl, 2-amino-4-methyl-phenyl, 4-halo-phenyl, 4-formylamino-pheπyl, 2- acetylamino-phenyl, 3-acetylamino-phenyl, 4-acetylamino-phenyl, N-3-phenyl- acetamide, N-4-phenyl-acetamide, N-4-phenyl-propionamide, N-4-phenyl- isobutyramide, N-4-ρhenyl-acrylamide, N-4-phenyl-benzamide, 4-(N,N-dimethyI- sulfonyl-amino)-phenyl, N-4-phenyl-2,2,2-trifluoro-acetamide trifluoro acetic acid, 4- phenyl-cyclopropanecarboxylic acid amide, 4-phenyloxy, 3,5-dihalo-phenyloxy, pheπyl-ethynyl, 2-ρyridyI, 3-pyridyl, 4-pyridyl, 2-pyridyl-thiomethyl or 5-trifluoromethyl- 2-pyridyl-thiomethyl;
R2 represents hydrogen or halo; and
R4 represents hydrogen, alkyl or halo.
11. The diazabicyclic aryl derivative of any one of claims 1 -4, represented by Formula III
Figure imgf000039_0001
any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically-acceptable addition salt thereof, wherein n is 1 , 2 or 3; and
X represents CR4 or N, wherein R4 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy;
R5 and R6, independently of each other, represent hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, cycloalkoxy, cyanoalkyl, halo, haloalkyl, haloalkoxy, cyano, amino, nitro, aryl, aryloxy, heteroaryl or heteroaryloxy.
12. The diazabicyclic aryl derivative of claim 11 , wherein R4 represents hydrogen or alkyl;
R5 represents hydrogen, alkyl or alkoxy; and R6 represents hydrogen, alkyl or alkoxy.
13. The diazabicyclic aryl derivative of claim 11 , which is (1,4-Diaza-bicyclo[3.2.2]non-4-yl)-8-methoxy-benzofuran-2-yl-methanone; (1,4-Diaza-bicyclo[3.2.2]non-4-yI)-benzofuran-2-yl-methanone; or (1,4-Diaza-bicyclo[3.2.2]non-4-yl)-3-methyl-benzofuran-2-yl-methanone; (1,4-Diaza-bicyclo[3.2.2]non-4-yl)-benzooxazol-2-yl-methanone; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
14. The diazabicyclic aryl derivative of any one of claims 1 -4, wherein
R1 represents a group of formula -(alkyl)m-Z-aryl, -(alkyl)m-Z-heteroaryl or -C≡C-aryl, wherein m is O or 1; and Z represents O or S; and wherein the aryl and heteroaryl may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH -, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl.
15. The diazabicyclic aryl derivative of claim 14, wherein
R1 represents a group of formula -CH2-Z-phenyl, -CH2-Z-pyridyl or -C≡C- phenyl, wherein m is O or 1; and
Z represents O or S; and wherein the phenyl and pyridyl group may optionally be substituted one or two times with alkyl, halo, haloalkyl, alkoxy, haloalkoxy, cyano, amino, nitro and/or a group of the formula R'CONH-, R'S02NH- or (R'S02)2N-, wherein R' represents hydrogen or alkyl.
16. The diazabicyclic aryl derivative of claim 15, which is (1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3,5-dichlorophenoxy)-furaπ-2-yl- methaπone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-[5-(trifluoromethyl-2-pyridyl)- thiomethyl]-furan-2-yl-methanone; or
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-phenyIethyπyl-furaπ-2-yl-methanone; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
17. The diazabicyclic aryl of any one of claims 1 -16, wherein n is 2.
18. The diazabicyclic aryl derivative of either one of claims 1 -2, wherein
R1 represents hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, halo, CF3, OCF3, CN, nitro, phenyl, 2-nitro-phenyl, 2-nitro-4-methyl-phenyl, 3-nitro-phenyl, 4- nitro-phenyl, 3-trifluoromethyl-ρhenyl, 4-trifluoromethyl-ρhenyl, 2-halo-5- trifluoromethyl-phenyl, 2-amino-pheπyl, 2-amino-4-methyl-phenyl, 3-amino-phenyl, 4- amino-phenyl, 2-amino-4-methyl-phenyl, 4-halo-phenyl, 4-formylamino-phenyl, 2- acetylamino-phenyl, 3-acetylamino-phenyl, 4-acetylamino-phenyl, N-3-phenyl- acetamide, N-4-phenyl-acetamide, N-4-phenyl-propionamide, N-4-phenyl- isobutyramide, N-4-phenyl-acrylamide, N-4-phenyl-benzamide, 4-(N,N-dimethyl- sulfonyl-amino)-phenyl, N-4-phenyl-2,2,2-trifluoro-acetamide trifluoro acetic acid, 4- phenyl-cyclopropanecarboxylic acid amide, 4-phenyloxy, 3,5-dihalo-phenyloxy, phenyl-ethynyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridyl-thiomethyl or 5-trifluoromethyl- 2-pyridyl-thiomethyl;
R2 represents hydrogen, alkyl or halo; and
R3 represents hydrogen, alkyl or halo.
9. The diazabicyclic aryl derivative of claim 18, which is
1,4-Diaza-bicyclo[3.2.2]non-4-yl ■furan-2-yl-methanone; 1,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-bromo-furan-2-yl-methanone; 1,4-Diaza-bicycIo[3.2.2]non-4-yl ■5-nitro-furan-2-yl-methanone; 1,4-Diaza-bicycIo[3.2.2]non-4-yl (5-phenyl-furan-2-yl)-methanone; 1,4-Diaza-bicyclo[3.2.2]non-4-yl -5-(4-nitrophenyl)-furan-2-yl-methanone; 1,4-Diaza-bicyclo[3.2.2]non-4-yl -5-(3-trifluoromethylphenyl)-furan-2-yl- methaπone
1,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(4-aminophenyl)-furan-2-yl-methanone; 1,4-Diaza-bicyclo[3.2.2]non-4-yI ■5-(4-chlorophenyl)-furan-2-yl-methanone; 1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(2-nitrophenyl)-furan-2-yl-methanoπe; 1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(3-nitrophenyl)-furan-2-yl-methanone; 1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(4-acetylamiπophenyl)-furan-2-yl- methanone
1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(2-aminophenyl)-furan-2-yl-methanone; 1 ,4-Diaza-bicyclo[3.2.2]non-4-yl •5-(3-aminophenyl)-furan-2-yl-methanone; 1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(2-acetylaminophenyl)-furan-2-yl- methanone
1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(3-acetylaminophenyl)-furan-2-yl- methanone;
(1 ,4-Diaza-bicyclo[3.2.2]non-4-yl ■3-methyl-furan-2-yl-methanone; (1,4-Diaza-bicyclo[3.2.2]non-4-yl ι-4,5-dibromo-furan-2-yl-methanone; (1,4-Diaza-bicyclo[3.2.2]noπ-4-yl ■5-(2-chloro-5-trifluoromethylphenyl)- furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl ■5-(2-nitro-4-methylphenyl)-furan-2-yl- methanone
1 ,4-Diaza-bicyclo[3.2.2]noπ-4-yl ■5-(2-amino-4-methylphenyl)-furan-2-yl- methanone
(1,4-Diaza-bicyclo[3.2.2]non-4-yl •5-[4-(N,N-dimethylsulfonyl)aminophenyl]- furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl -5-(4-formylaminophenyl)-furan-2-yl- methanone; N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- propionamide;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(3,5-dichlorophenoxy)-furan-2-yl- methanone;
(1,4-Diaza-bicyclo[3.2.2]non- -yl)-5-[5-(trifluoromethyl-2-pyridyl)- thiomethyl]-furan-2-yl-methanoπe;
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- 2,2,2-trifluoro-acetamide trifluoro acetic acid;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-3-bromo-furan-2-yl-methanone;
(1,4-Diaza-bicyclo[3.2.2]noπ-4-yl)-5-pheπylethyπyl-furan-2-yl-methanone;
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- acrylamide;
N-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- benzamide;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-[4-(N,N-diphenylsulfonylamino)phenyl]- furan-2-yl-methanone;
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- isobutyramide;
Cyclopropanecarboxylic acid {4-[5-(1 ,4-diaza-bicyclo[3.2.2]nonane-4- carbonyl)-furan-2-yl]-phenyl}-amide;
(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-5-(4-aminophenyl)-furan-2-yl-methanone;
N-{4-[5-(1,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- acrylamide N-oxide; or
N-{4-[5-(1 ,4-Diaza-bicyclo[3.2.2]nonane-4-carbonyl)-furan-2-yl]-phenyl}- acrylamide; an enantiomers or a mixture of its enantiomers, or a pharmaceutically- acceptable addition salt thereof.
20. A pharmaceutical composition comprising a therapeutically effective amount of a diazabicyclic aryl derivative of any one of claims 1-19, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
21. Use of a diazabicyclic aryl derivative of any one of claims 1 -19, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition/medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors.
22. The use according to claim 21, wherein the disease, disorder or condition relates to the central nervous system.
23. The use according to claim 22, wherein the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, periferic neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser"s syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania and jet-lag.
24. The use according to claim 21 , wherein the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskiπesia, hyperkinesia, premature ejaculation and erectile difficulty.
25. The use according to claim 21, wherein the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
26. The use according to claim 21 , wherein the disease, disorder or condition is a πeurodegenerative disorders, including transient anoxia and induced neuro-degeneration.
27. The use according to claim 21, wherein the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis and diarrhoea.
28. The use according to claim 21, wherein the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as neuropathic pain and pain caused by migraine, postoperative pain, phantom limb pain, neuropathic pain, chronic headache, central pain, pain related to diabetic neuropathy, to post therapeutic neuralgia, or to peripheral nerve injury.
29. The use according to claim 21, wherein the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs and alcohol.
30. A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors, which method comprises the step of administering to such a living animal body in need thereof a therapeutical ly effective amount of a diazabicyclic aryl derivative of any one of claims 1-19.
PCT/EP2004/050079 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives WO2004076453A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MXPA05006861A MXPA05006861A (en) 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives.
EP04707948A EP1599476B1 (en) 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives
AU2004215658A AU2004215658B2 (en) 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives
JP2006502001A JP2006519208A (en) 2003-02-27 2004-02-04 Novel diazabicycloaryl derivatives
US10/547,157 US7678788B2 (en) 2003-02-27 2004-02-04 Diazabicyclic aryl derivatives
NZ540998A NZ540998A (en) 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives
DE602004023586T DE602004023586D1 (en) 2003-02-27 2004-02-04 NEW DIAZABICYCLIC ARYL DERIVATIVES
BR0407216-2A BRPI0407216A (en) 2003-02-27 2004-02-04 Diazabically cyclic arila derivative, pharmaceutical composition, use of a diazabically cyclic arila derivative, and, method of treatment, prevention or alleviation of a disease or disorder or condition
CA002518675A CA2518675A1 (en) 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives
AT04707948T ATE445618T1 (en) 2003-02-27 2004-02-04 NEW DIAZABICYCLIC ARYL DERIVATIVES
HK06104352A HK1084110A1 (en) 2003-02-27 2006-04-11 Novel diazabicyclic aryl derivatives
US12/694,952 US20100130483A1 (en) 2003-02-27 2010-01-27 Novel diazabicyclic aryl derivatives

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US44987103P 2003-02-27 2003-02-27
DKPA200300310 2003-02-27
US60/449,871 2003-02-27
DKPA200300310 2003-02-27
DKPA200300940 2003-06-24
DKPA200300940 2003-06-24
US48202203P 2003-06-25 2003-06-25
US60/482,022 2003-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/694,952 Division US20100130483A1 (en) 2003-02-27 2010-01-27 Novel diazabicyclic aryl derivatives

Publications (1)

Publication Number Publication Date
WO2004076453A1 true WO2004076453A1 (en) 2004-09-10

Family

ID=32931427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/050079 WO2004076453A1 (en) 2003-02-27 2004-02-04 Novel diazabicyclic aryl derivatives

Country Status (11)

Country Link
US (2) US7678788B2 (en)
EP (1) EP1599476B1 (en)
JP (1) JP2006519208A (en)
AT (1) ATE445618T1 (en)
AU (1) AU2004215658B2 (en)
BR (1) BRPI0407216A (en)
CA (1) CA2518675A1 (en)
DE (1) DE602004023586D1 (en)
MX (1) MXPA05006861A (en)
NZ (1) NZ540998A (en)
WO (1) WO2004076453A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075479A1 (en) * 2004-02-04 2005-08-18 Neurosearch A/S Dimeric azacyclic compounds and their use
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
WO2008057938A1 (en) * 2006-11-02 2008-05-15 Targacept, Inc. Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
WO2009071576A1 (en) * 2007-12-05 2009-06-11 Glaxo Group Limited 5-aryl-1,3,4-oxadiazole-2-amines as nicotinic acetylcholine receptor agonists
DE102008062878A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted furancarboxamides and their use
EP1713810B1 (en) * 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
EP2409703A1 (en) 2007-08-02 2012-01-25 Targacept, Inc. Treatment with alpha7-selective ligands
US8314089B2 (en) 2008-03-17 2012-11-20 Aicuris Gmbh & Co. Kg Substituted pyrazolamides and their use
US8399682B2 (en) 2008-03-17 2013-03-19 Aicuris Gmbh & Co. Kg Substituted (pyrazolylcarbonyl)imidazolidinones and their use
US8476296B2 (en) 2009-01-26 2013-07-02 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US8546438B2 (en) 2008-12-17 2013-10-01 Kai Thede Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof
US10537539B2 (en) 2009-09-22 2020-01-21 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202430D0 (en) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (en) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
TW200529860A (en) * 2003-12-22 2005-09-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CN106986862A (en) 2010-12-22 2017-07-28 Abbvie 公司 Hepatitis c inhibitor and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058311A1 (en) 1999-03-30 2000-10-05 Sanofi-Synthelabo 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics
EP1231212A1 (en) * 2001-02-06 2002-08-14 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
US6552012B2 (en) * 1999-05-04 2003-04-22 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
FR2832712A1 (en) * 2001-11-23 2003-05-30 Sanofi Synthelabo New 4-(1,2,4-oxadiazol-3-yl)-1,4-diaza-bicyclo (3.2.2) nonane derivatives, are nicotinergic receptor ligands useful for treating central nervous system diseases such as Alzheimer's disease or schizophrenia
FR2832713A1 (en) * 2001-11-23 2003-05-30 Sanofi Synthelabo New 4-(1,3,4-thiadiazol-2-yl)-1,4-diaza-bicyclo(3.2.2)nonane derivatives, are nicotinergic receptor ligands useful for treating central nervous system diseases such as Alzheimer's disease or schizophrenia
US20030119837A1 (en) * 2000-12-29 2003-06-26 Pfizer Inc. Pharmaceutical composition for the treatment of CNS and other disorders
US20030119840A1 (en) * 2000-01-28 2003-06-26 Frederic Galli 4-Heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122339B2 (en) * 1998-10-09 2006-10-17 Medical Research Council Method for generating diversity
FR2809731B1 (en) * 2000-05-31 2002-07-19 Sanofi Synthelabo 1,4-DIAZABICYCLO- [3.2.2] NONANE-PHEYLISOXAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2809730B1 (en) * 2000-05-31 2002-07-19 Sanofi Synthelabo 1,4-DIAZABICYCLO [3.2.2] NONANEBENZOXAZOLE, -BENZOTHIAZOLE AND -BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AU2002311553A1 (en) 2002-06-26 2004-01-19 Nokia Corporation Method and network element for optimisation of radio resource utilisation in a radio access network
SE0202430D0 (en) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (en) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
ATE426602T1 (en) 2002-09-30 2009-04-15 Neurosearch As 1,4-DIAZABICYCLOACANDERIVATES, THEIR PREPARATION AND USE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058311A1 (en) 1999-03-30 2000-10-05 Sanofi-Synthelabo 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics
US6552012B2 (en) * 1999-05-04 2003-04-22 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
US20030119840A1 (en) * 2000-01-28 2003-06-26 Frederic Galli 4-Heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof
US20030119837A1 (en) * 2000-12-29 2003-06-26 Pfizer Inc. Pharmaceutical composition for the treatment of CNS and other disorders
EP1231212A1 (en) * 2001-02-06 2002-08-14 Pfizer Products Inc. Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
FR2832712A1 (en) * 2001-11-23 2003-05-30 Sanofi Synthelabo New 4-(1,2,4-oxadiazol-3-yl)-1,4-diaza-bicyclo (3.2.2) nonane derivatives, are nicotinergic receptor ligands useful for treating central nervous system diseases such as Alzheimer's disease or schizophrenia
FR2832713A1 (en) * 2001-11-23 2003-05-30 Sanofi Synthelabo New 4-(1,3,4-thiadiazol-2-yl)-1,4-diaza-bicyclo(3.2.2)nonane derivatives, are nicotinergic receptor ligands useful for treating central nervous system diseases such as Alzheimer's disease or schizophrenia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Reminqton's Pharmaceutical Sciences", MAACK PUBLISHING CO.
JAQUES J; COLLET A; WILEN S: "Enantiomers, Racemates, and Resolutions", 1981, JOHN WILEY AND SONS

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US7371822B2 (en) 2003-03-14 2008-05-13 Bristol-Myers Squibb Company Human G-protein coupled receptor variant of HM74, HGPRBMY74
US7674899B2 (en) 2004-02-04 2010-03-09 Neurosearch A/S Dimeric azacyclic compounds and their use
WO2005075479A1 (en) * 2004-02-04 2005-08-18 Neurosearch A/S Dimeric azacyclic compounds and their use
EP1713810B1 (en) * 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
US8268860B2 (en) 2006-11-02 2012-09-18 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
CN102942569A (en) * 2006-11-02 2013-02-27 塔加西普特公司 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
US9580434B2 (en) 2006-11-02 2017-02-28 Attenua, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
KR101415705B1 (en) 2006-11-02 2014-07-04 타가셉트 인코포레이티드 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
EP2284171A1 (en) * 2006-11-02 2011-02-16 Targacept, Inc. Amides of diazabicycloalkanes selective for nicotinic acetylcholine receptor sub-types
US8859609B2 (en) 2006-11-02 2014-10-14 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
US8114889B2 (en) 2006-11-02 2012-02-14 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
RU2448969C2 (en) * 2006-11-02 2012-04-27 Таргасепт, Инк. Amides of diazabicycloalkanes, selective with respect to acetylcholine subtype of nicotine receptors and pharmaceutic composition and methods of treatment with their application
US8921410B2 (en) 2006-11-02 2014-12-30 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
RU2517693C2 (en) * 2006-11-02 2014-05-27 Таргасепт, Инк. Amides of diasabicycloalkanes, selective with respect to acetylcholine subtype of nicotinic receptors
WO2008057938A1 (en) * 2006-11-02 2008-05-15 Targacept, Inc. Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes
CN102942569B (en) * 2006-11-02 2015-10-28 塔加西普特公司 The acid amides of alkalescence acetylcholine receptor subtypes optionally diazabicylo alkane
CN102838605A (en) * 2006-11-02 2012-12-26 塔加西普特公司 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
CN102838605B (en) * 2006-11-02 2017-04-26 塔加西普特公司 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
EP2484363A1 (en) 2007-08-02 2012-08-08 Targacept, Inc. (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide
EP2409703A1 (en) 2007-08-02 2012-01-25 Targacept, Inc. Treatment with alpha7-selective ligands
WO2009071576A1 (en) * 2007-12-05 2009-06-11 Glaxo Group Limited 5-aryl-1,3,4-oxadiazole-2-amines as nicotinic acetylcholine receptor agonists
US8314089B2 (en) 2008-03-17 2012-11-20 Aicuris Gmbh & Co. Kg Substituted pyrazolamides and their use
US8399682B2 (en) 2008-03-17 2013-03-19 Aicuris Gmbh & Co. Kg Substituted (pyrazolylcarbonyl)imidazolidinones and their use
US8546438B2 (en) 2008-12-17 2013-10-01 Kai Thede Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof
US8324268B2 (en) 2008-12-17 2012-12-04 Aicuris Gmbh & Co. Kg Substituted furancarboxamides, and use thereof
WO2010075957A1 (en) 2008-12-17 2010-07-08 Aicuris Gmbh & Co. Kg Substituted furancarboxamides, and use thereof
DE102008062878A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted furancarboxamides and their use
US8476296B2 (en) 2009-01-26 2013-07-02 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US8901151B2 (en) 2009-01-26 2014-12-02 Targacept, Inc. Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide
US9173876B2 (en) 2009-01-26 2015-11-03 Targacept, Inc. Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US10537539B2 (en) 2009-09-22 2020-01-21 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
US11096916B2 (en) 2009-09-22 2021-08-24 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators

Also Published As

Publication number Publication date
AU2004215658A1 (en) 2004-09-10
BRPI0407216A (en) 2006-01-24
DE602004023586D1 (en) 2009-11-26
EP1599476B1 (en) 2009-10-14
US20060148789A1 (en) 2006-07-06
MXPA05006861A (en) 2005-12-12
EP1599476A1 (en) 2005-11-30
NZ540998A (en) 2008-06-30
AU2004215658B2 (en) 2010-06-24
CA2518675A1 (en) 2004-09-10
JP2006519208A (en) 2006-08-24
US7678788B2 (en) 2010-03-16
ATE445618T1 (en) 2009-10-15
US20100130483A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
US20100130483A1 (en) Novel diazabicyclic aryl derivatives
US8236793B2 (en) Diazabicyclic aryl derivatives as cholinergic receptor modulators
ES2280836T3 (en) NEW DERIVATIVES OF 1,4-DIAZABICICLOALCANO, ITS PREPARATION AND USE.
AU2007267174B2 (en) Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use
US20100130482A1 (en) Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US20080280912A1 (en) Novel Diazabicycylic Aryl Derivatives and Their Medical Use
US7514450B2 (en) Azabicyclic aryl derivatives
US20040127491A1 (en) Novel diazabicyclic biaryl derivatives
AU2009224737A1 (en) Novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors
US7612074B2 (en) Diazabicyclic aryl derivatives as cholinergy ligands
WO2010086280A1 (en) Novel n-oxides of furanyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
EP1987032A1 (en) 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists
RU2338746C2 (en) New diazabicyclic aryl derivatives, pharmaceutical compositions containing them and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004707948

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006861

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 540998

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20048024231

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004215658

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004215658

Country of ref document: AU

Date of ref document: 20040204

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004215658

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006502001

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2006148789

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10547157

Country of ref document: US

Ref document number: 2058/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2518675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005118997

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004707948

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407216

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10547157

Country of ref document: US